Kallikreins cleave plasma kininogens to release the bioactive peptides bradykinin (BK) or kallidin (Lys-BK). These peptides then activate widely disseminated B 2 receptors with consequences that may be either noxious or beneficial. We used cultured cells to show that kallikrein can bypass kinin release to activate BK B 2 receptors directly. To exclude intermediate kinin release or kininogen uptake from the cultured medium, we cultured and maintained cells in medium entirely free of animal proteins. We compared the responses of stably transfected Chinese hamster ovary (CHO) cells that express human B 2 receptors (CHO B2) and cells that coexpress angiotensin I-converting enzyme (ACE) as well (CHO AB). We found that BK (1 nM or more) and tissue kallikrein (1-10 nM) both significantly increased release of arachidonic acid beyond unstimulated baseline level. An enzyme-linked immunoassay for kinin established that kallikrein did not release a kinin from CHO cells. We confirmed the absence of kininogen mRNA with RT-PCR to rule out kininogen synthesis by CHO cells. We next tested an ACE inhibitor for enhanced BK receptor activation in the absence of kinin release and synthesized an ACE-resistant BK analog as a control for these experiments. Enalaprilat (1 M) potentiated kallikrein (100 nM) in CHO AB cells but was ineffective in CHO B 2 cells that do not bear ACE. We concluded that kallikrein activated B 2 receptors without releasing a kinin. Furthermore, inhibition of ACE enhanced the receptor activation by kallikrein, an action that may contribute to the manifold therapeutic effects of ACE inhibitors. arachidonic acid; angiotensin I-converting enzyme inhibitor; kallidin; immunoassay THE FUNCTIONS of the kallikrein-kinin system have been widely studied since the discovery of its components (1, 14, 19, 46) . For example, decrease in urinary excretion of kallikrein is a characteristic feature of clinical or experimentally induced hypertension (36). Kinins release potent vasodilators, such as PGs, nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF) (3-5), which influence blood pressure and vessel tone, but they can cause pain and enhance capillary permeability in inflammation as well (3). The beneficial effects of angiotensin I-converting enzyme (ACE) (18, 40) or kininase II inhibitors are attributed at least in part to prolongation of the half-life of bradykinin (BK) (6 -8, 20 -22) and potentiation of its effects on the B 2 receptor (15, (33) (34) (35) . Although plasma kininogen is the primary substrate of kallikreins, these serine proteases can cleave other proteins as well, such as factor XII, the activator of prokallikrein (12, 41, 42) . Generation of BK or kallidin (Lys-BK) by kallikrein results from a complex, multistep enzymatic cascade starting with prokallikrein activation and ending with kinin release from plasma kininogen (12, 29, 32, 41, 42) . The peptides must then evade cleavage by the kininases we characterized, such as carboxypeptidase N or M as kininase I and ACE and neprilysin as kininase II, to activate the B 2 receptors (3, 16, 26, 43, 47) . When carboxypeptidases N or M cleave the COOH-terminal arginine from either BK or Lys-BK (14, 44), the resulting des-Arg kinins become ligands for the second kinin receptor B 1 (3).
arachidonic acid; angiotensin I-converting enzyme inhibitor; kallidin; immunoassay THE FUNCTIONS of the kallikrein-kinin system have been widely studied since the discovery of its components (1, 14, 19, 46) . For example, decrease in urinary excretion of kallikrein is a characteristic feature of clinical or experimentally induced hypertension (36) . Kinins release potent vasodilators, such as PGs, nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF) (3) (4) (5) , which influence blood pressure and vessel tone, but they can cause pain and enhance capillary permeability in inflammation as well (3) . The beneficial effects of angiotensin I-converting enzyme (ACE) (18, 40) or kininase II inhibitors are attributed at least in part to prolongation of the half-life of bradykinin (BK) (6 -8, 20 -22) and potentiation of its effects on the B 2 receptor (15, (33) (34) (35) . Although plasma kininogen is the primary substrate of kallikreins, these serine proteases can cleave other proteins as well, such as factor XII, the activator of prokallikrein (12, 41, 42) . Generation of BK or kallidin (Lys-BK) by kallikrein results from a complex, multistep enzymatic cascade starting with prokallikrein activation and ending with kinin release from plasma kininogen (12, 29, 32, 41, 42) . The peptides must then evade cleavage by the kininases we characterized, such as carboxypeptidase N or M as kininase I and ACE and neprilysin as kininase II, to activate the B 2 receptors (3, 16, 26, 43, 47) . When carboxypeptidases N or M cleave the COOH-terminal arginine from either BK or Lys-BK (14, 44) , the resulting des-Arg kinins become ligands for the second kinin receptor B 1 (3) .
Because activation of B 2 receptors has such important consequences in many diverse tissues, we considered that another pathway, a shunt, may activate B 2 receptors independent of the complex enzymatic cascade required for kinin release (23) (24) (25) . Similar dual backup systems occur in numerous other biological reactions. Indeed, we found that B 2 receptors can be activated directly by kallikreins and certain other serine proteases. The BK B 2 receptors, similar to the protease-activated receptors (PAR) 1-4 of thrombin or trypsin (38) , belong to a G protein-linked, hepta-helical transmembrane receptor group that is activated by serine proteases. However, our experiments with cultured cells of various origins indicate that activation of the BK B 2 receptor proceeds through a different mechanism than for PARs by thrombin or thrombin receptor activator peptide (TRAP) ligand (24) .
Culture of specialized mammalian cells usually requires a rich medium that contains 5-10% fetal bovine serum. Previously, we used cells washed free of added proteins (23, 25) or washed and serum-starved. Nevertheless, we wanted to exclude a possibility that proteases could activate B 2 receptors by cleaving traces of adherent kininogen. Consequently, we have grown and maintained cells transfected with human BK B 2 receptors, or B 2 and ACE, in media entirely free of serum and animal proteins.
We measured release of [ 3 H]arachidonic acid (AA) from Chinese hamster ovary (CHO) cells and found that kallikreins activated transfected human BK B 2 receptors in the absence of any cell-bound kininogen. We also investigated the effects of ACE inhibitors, because these agents appear to potentiate kinin effects through cross talk between ACE and B 2 receptors (15, (33) (34) (35) . The results from these experiments enabled us to exclude kinin release as a mechanism for kallikrein activation of B 2 receptors. We showed that ACE inhibitors potentiated the actions of kallikrein by a mechanism independent of kinin inactivation also by employing an ACE-resistant BK analog in CHO cells expressing human ACE and B 2 receptors. [didansyl-Lys-BK (didansyl-kallidin; DidnsKD)] that rendered it resistant to ACE (11) .
MATERIALS AND METHODS

Materials
Cell culture. Initially, CHO cells were grown in 100-mm petri dishes in Ham's F-12 culture medium (Cellgro), supplemented with antibiotic and 10% fetal bovine serum under 5% CO 2 and a watersaturated environment. Cells were routinely subcultured with the use of trypsin-EDTA for detachment and transfer. CHO cells stably transfected with either BK B 2 receptor or both ACE and B2 receptor were adapted to culture in PFAF medium for attached cells (Sigma). The medium was supplemented with 200 mM L-glutamine, and the cultures were maintained at 37°C under 5% CO 2 in a water-saturated environment. The cells were subcultured by rinsing with the same serum-free medium, and they were then scraped and transferred to 100-mm petri dishes in fresh medium. For measurements of AA release and other experiments, cells were cultured in CHO PFAF medium for at least 8 -10 passages to exclude artifacts from prior exposure to fetal calf serum before transfer into 12-well plates for experiments.
Transfection with human B 2 receptor cDNA and human ACE cDNA. pcDNA3 plasmid containing human BK B 2 receptor was used to transfect CHO cells (24, 25) . To obtain CHO cells that coexpress both human ACE and BK B 2 receptor (AB), the cells were first transfected with human ACE pcDNA6 plasmid, and individual clones were screened for ACE activity (11, 34) . Clones with high ACE activity were then transfected with human BK B 2 receptor cDNA as described above (CHO AB cells; 33).
[ 3 H]AA release. Experiments were performed essentially as previously described (11, 24) . Briefly, the cells were grown to confluence in a 12-well dish. The medium was replaced with 1 ml of culture medium containing 0.5 mCi/ml of [ 3 H]AA, and cells were loaded for 16 h at 37°C. After three washings with incubation medium (Ham's F-12 medium containing 0.1% albumin), the cells were incubated for 10 min at 37°C in the presence of enalaprilat (1 M). Kallikrein, DidnsKD, or other agonist was then added, and cells were incubated for an additional 20 min at 37°C. In parallel samples we added a B 2 receptor blocker, HOE-140, before the addition of the test reagent. After completion of the incubation, the medium was removed and the [ 3 H]AA content was measured in a scintillation counter. To trap released [ 3 H]AA and block its reuptake, we added albumin that adsorbed the [ 3 H]AA to be counted. We used defatted BSA in some experiments and crystallized albumin in others, but the results were the same. Neither preparation had contaminating kininogen.
ELISA. Enzyme immunoassays used a high-sensitivity kit for BK (Bachem) according to the manufacturer's protocol. Briefly, 50 l of standard solutions or test samples were added to immunoplate multiwells, 25 l of each primary antisera and biotinylated peptide solution were then added, and the plates were incubated for 2 h at room temperature with mild agitation. The plates were then washed five times, and 100 l of diluted streptavidin-conjugated horseradish peroxidase solution was added to each well. After a 60-min incubation at room temperature, the immunoplates were washed five times, and 100 l of 3,3Ј,5,5Ј-tetramethyl benzidine dihydrochloride (TMB) solution was added to each well. After a further 20-min incubation at room temperature, the reaction was stopped with 100 l of 2 N HCl. Absorbance was read at 450 nm, using 100 l of TMB solution and 100 l 2 N HCl as a blank control.
Radioligand binding. (24) . After 1 h incubation at 4°C, cells were washed three times with serum-free Ham's F-12 medium; solubilized in 0.5 ml of a solution containing 0.1 M NaOH, 0.1 M NaHCO 3, and 1% SDS; and counted. Nonspecific binding was determined in the presence of 10 M unlabeled BK, and specific binding was calculated as the difference between total and nonspecific binding. CHO AB/PFAF cells were preincubated with ACE inhibitor enalaprilat (1 M) for 20 min before adding BK.
In radioligand displacement experiments, ϳ1 nM [ 3 H]BK competed for the binding with increasing concentrations of DidnsKD (ranging from 10 Ϫ12 to 10 Ϫ4 M). As a control, homologous displacement using unlabeled BK was performed.
Total RNA/mRNA isolation. We used RNA STAT-60 isolation reagent according to the manufacturer's protocol. The cells were lysed by using RNA STAT-60 and homogenized, chloroform was then added, and the samples were vortexed and held at room temperature for 2-3 min. All samples were centrifuged at 12,000 g for 15 min at 4°C, and the aqueous phase was transferred to a fresh tube and mixed with isopropanol. After 10-min incubation at room temperature, the samples were centrifuged at 12,000 g for 10 min at 4°C. The resulting RNA pellet was washed with 75% ethanol by vortexing and centrifugation at 7,500 g for 5 min at 4°C. The samples were then air-dried briefly and dissolved in RNase-free water.
RT-PCR. We used SuperScript one-step RT-PCR with Platinum Taq kit (Invitrogen) according to the manufacturer's protocol. PCR primers for kininogen (KNG) were KNG3 (5Ј-GCCCAGAGCT-GAAGGAGG) and KNG4 (5Ј-CATGTACACGTTAGCATTGCAG), and GAPDH1 (5Ј-CGACCCCTTCATTGACCTC) and GAPDH2 (5Ј-CTCCACGACATACTCAGCACC) for GAPDH.
Statistical analysis. Values as means Ϯ SE were calculated for the experiments, and statistical significance of differences between means was tested by a paired t-test (Microsoft Excel).
RESULTS
CHO cells in serum-free medium. CHO cells stably transfected with human BK B 2 (CHO B 2 ) receptors were grown and maintained in medium entirely free of animal proteins for eight or more passages. Activation of the B 2 receptor on these cells released [ 3 H]AA, presumably by a mechanism involving a G␣ i protein coupled to the receptor, which in turn activates phospholipase A 2 (4) . With basal release as 1.0, ( ELISA. To rule out any possible release of BK by kallikrein from kininogen expressed by or adhering to CHO B 2 cells even in protein-free medium, we used an ELISA for BK. The linear portion of the assay standard curve ranged from 2 ϫ 10 Ϫ9 to 1 ϫ 10 Ϫ10 M BK in Ͼ4 experiments. Tissue kallikrein (10 nM) was tested first by adding it to a medium containing 10% fetal bovine serum. It released BK in excess of 10 Ϫ8 M in 30 min. Serum-free culture medium and conditioned medium from kallikrein-treated cells were assayed along with appropriate reagent controls. We measured only a basal value 0.2 ng/ml from protein-free medium sampled both in the presence or absence of CHO B 2 cells (data not shown); these findings confirm the absence of kininogen on cell membranes or in the culture medium. Because immunoreactivity of the medium collected from kallikrein-treated (10 nM) cells did not exceed the reagent baseline, we concluded that kallikrein failed to release kinin from either cell-free medium or CHO B 2 cells and that the enzyme activated the BK B 2 receptor by another mechanism.
Lack of kininogen expression. We considered the possibility that CHO cells constitutively express kininogen, even when grown in protein-free medium, so we used RT-PCR to test for kininogen expression. Because the exact sequence of hamster kininogen was not available, primers were synthesized from identical regions found after comparison of sequences from rat (Rattus norvegicus) kininogen 1 and mouse (Mus musculus) kininogen 2 mRNA (obtained from GenBank). We also synthesized primers based on identical regions of rat and mouse GAPDH mRNA sequences for RNA quality control. The total RNA isolated from CHO B 2 cells cultured in serum-free medium was compared with the total RNA from rat and hamster liver. RNA was isolated with RNA STAT-60 and quantified by measuring UV absorbance at 260 nm. As control kininogen cDNA fragments of expected size (ϳ247 bp) were amplified from 50 ng rat liver RNA after 35 cycles. Samples not subjected to RT-PCR had no detectable signal (not shown). Similarly, CHO B 2 cell RNA mixtures, either with or without reverse transcription, yielded no detectable bands. In hamster liver RNA samples, strong bands of kininogen cDNA appeared with RT-PCR after 35 cycles with the use of 50 or 500 ng RNA (Fig. 2A) . The 200 bp cDNA fragments of GAPDH were amplified by RT-PCR from either the CHO B2 cells RNA preparation or the rat liver RNA preparation (Fig. 2B) .
Kininogens originate mainly from the liver in mammalian species (3) . Thus the rat and hamster livers were strongly positive, showing appreciable amounts of mRNA, but cultured CHO cells lacked kininogen mRNA, confirming the results of our experiments (23, 25) (Fig. 3) . We also used the ACE-resistant peptide DidnsKD as a positive control. This B 2 receptor agonist resists degradation by ACE by 97% (11), because dansylation of both ␣-and ⑀-NH 2 groups of Lys 1 blocks hydrolysis by ACE, which cleaves peptides only of restricted size (13, 16, 43 (Fig. 3) , and it was inhibited by HOE-140 (0.5 M). Enalaprilat potentiates only active kallikrein. When inhibited by crystalline aprotinin (1 M; Fig. 4A) , it was inactive and enalaprilat had no effect.
Lack of ACE expression. To show that the ACE inhibitor is effective only when both B 2 receptors and ACE are expressed, we tested CHO B 2 cells that have no ACE. CHO B 2 cells also lack B 1 receptors that might be activated by an ACE inhibitor (28) . Figure 4B shows that, as previously noted (15), enalaprilat was ineffective in the absence of ACE. It failed to enhance [ 3 H]AA release by either BK or kallikrein (n Ն 3 experiments). We concluded that kallikrein must be active to act as a B 2 receptor agonist (25) , and to be potentiated by an ACE inhibitor requires the expression of ACE.
Finally, we used an ELISA to see whether enalaprilat might increase the putative presence of BK locally by blocking its inactivation by CHO AB/PFAF cells. However, cells pretreated with enalaprilat (1 M) before stimulation by kallikrein did not release BK (results not shown). BK was absent in the samples with or without added enalaprilat, allowing us to rule out BK release or protection from degradation as a cause of enhanced AA release.
DISCUSSION
We found that cells grown and maintained in protein-free medium can be activated by kallikrein, despite the fact that they were never exposed to plasma kininogen, the precursor of kinins. Human plasma has two kininogens. These proteins, high and low molecular weight kininogen, are products of the same gene; both are synthesized in the liver and released into circulation (3, 14) . Plasma kallikrein cleaves the high molecular weight substrate, whereas tissue kallikrein hydrolyzes both proteins. When blood coagulates, much of the plasma kininogen is metabolized, which is likely what happens to the fetal bovine serum commonly used to supplement media for cultured cells.
Nevertheless, in our experiments we eliminated the possibilities that kallikrein activated the B 2 receptors of cultured cells because of the presence of kininogen. Initially, we used serum-starved CHO cells to exclude the possibility of an uptake of kininogen from the medium. Next, although Zn 2ϩ facilitate adsorption of kininogen from the medium to the cell membrane (29, 41, 42) , we demonstrated previously that activation of B 2 receptors by kallikrein was unaffected in the absence of zinc (25) . Here we report that cells were cultured in entirely serum-free medium. When we applied an ELISA to measure putative kinin release from these cells, the results were negative. Finally, to eliminate the possibility that the CHO cells could synthesize kininogen, we showed that the cells we used lack kininogen mRNA. Taken together, these findings effectively eliminate participation of kinin release by kallikrein as a mechanism of BK B 2 receptor activation in our studies. ACE inhibitors are successfully used in therapy for a variety of cardiovascular diseases (18, 20, 22, 40) . At least part of the effects of an ACE inhibitor may depend on actions beyond blocking the inactivation of BK by ACE, specifically the direct potentiation of BK at its B 2 receptors (33-35) . Although the first clinically tested ACE inhibitor was a peptide derived from the so-called BK potentiating factor in snake venom (22) , BK potentiation and kininase ACE inhibition were not parallel (15) . Indeed, they differed a great deal in a series of synthetic peptide congeners (37) ; peptides also potentiated in the absence of ACE expression. Synthetic ACE inhibitors can enhance the actions of BK on its B 2 receptors by a cross talk between the receptor and ACE (15) . For this reason, we wondered whether ACE inhibitors would potentiate kallikrein effects on the BK B 2 receptors in a similar manner. To confirm that potentiation occurred in the absence of kinin generation and independent of BK inactivation, we synthesized a BK analog (DidnsKD) with a modified NH 2 terminus. This structural change rendered the peptide almost entirely (97%) resistant to ACE (11) . ACE inhibitor can enhance ACE and cyclooxygenase-2 expression in endothelial cells. This involves the phosphorylation of Ser 1270 of the COOH-terminal cytosolic sequence of ACE (30, 31) . Our acute experiments would unlikely involve protein synthesis, which may take 24 -36 h (30, 31) . ACE inhibitor potentiated BK and resensitized B 2 receptors to the peptide; even when in a mutated, truncated ACE, the COOH-terminal 19 amino acids of the cytosolic portions of human ACE were deleted (33), thus very likely in the absence of phosphorylation.
Enalaprilat had no effect on the release of [ 3 H]AA from labeled CHO B 2 cells in serum-free medium. These cells were transfected to express B 2 receptors but lacked ACE. In contrast, the addition of the ACE inhibitor to CHO cells that stably express both human ACE and B 2 receptors potentiated the effect of kallikrein and an ACE-resistant BK analog. These findings suggest that an additional contribution to the multiple beneficial effects of ACE inhibitors could include the enhanced activation of B 2 receptors by kallikrein.
We reported that kallikreins (tissue or plasma) activate B 2 receptors differently than BK. For example, kallikreins and BK both desensitized B 2 receptors, but there was no cross-desensitization (25) . Experiments with a carboxypeptidase BK inactivator and site-directed mutagenesis underscored the differences between the protease and the peptide B 2 agonists. Our investigations confirm that ACE inhibitors act beyond blocking kinin inactivation by ACE. Enalaprilat enhanced both the ACE-resistant BK analog and kallikrein activity in an apparently kinin-free system. Because ACE and B 2 can form heterodimers (33) and can colocalize closely on cell membranes (Chen Z, Tan F, Erdös EG, and Deddish PA, unpublished data), our findings suggest that ACE inhibitors may induce conformational changes via ACE, acting as indirect allosteric enhancers (9) of BK B 2 receptor agonists. Once the receptor is activated, the mechanism presumably follows a common path, namely, the coupling G␣ i protein and then phospholipase A 2 activation.
Over the long history of kallikrein research, some experimental results could not be explained by kallikreins acting exclusively on plasma kininogen to release a kinin (45) . For example, rat urinary kallikrein or trypsin applied at short intervals stimulated the isolated estrogen-primed rat uterus repeatedly (2, 10, 17) . This repetitive action on the isolated organ cannot be due to a continuous replenishment of kininogen.
Furthermore, kallikreins release one molecule of kinin from each kininogen molecule, and the liberated kinins are rapidly cleaved by kininases. Kallidin (Lys-BK) is converted to BK by the removal of the NH 2 -terminal Lys (16) . The half-life of injected BK is only 15-20 s, indicating that kinin release and action would necessarily occur within a discrete, local environment. In this regard, kinins function as paracrine agents (8) . Kinin generation requires a very rapid reaction where possibly only a fraction of the kininogen substrate is cleaved. If only 10% of the plasma protein kininogen substrate was hydrolyzed, high or low molecular weight kininogen with a molecular mass of ϳ50 or 100 kDa would need to be in 500-to 1,000-fold excess to release a single molecule of BK (1 kDa) near to a receptor. This assumption then raises the question as to whether this weight ratio would always be obtained at the outer surface of cellular plasma membranes.
The direct activation of the human B 2 peptide receptor (25, 27) offers an alternative pathway of activation for this multistep enzymatic process. We have identified such a pathway in cultured cells, and we believe that this mechanism may explain some of the phenomena associated with the therapeutic actions of ACE inhibitors in vivo.
